PHARMACOKINETICS

Repeated doses of PB1046 up to 0.8 mg/kg were safe and well tolerated.

The difference (highest to lowest mean values) in mean seated SBP (triplicate measurements taken 1 minute apart for each subject at each time point) was 16.9 mmHg (range: 1.6 to 33.0 mmHg), with a maximum excursion of 33.0 mmHg. These differences were not considered to be clinically meaningful.

Conclusions

PB1046 exhibited the anticipated (by design) slow absorption and extended half-life profile at the highest dose tested but with no significant effect on heart rate.

rückblick auf die vorangegangenen Punkte: Die Untersuchungsergebnisse zeigen, dass PB1046 eine stabile und verträgliche Wirkung aufказывает, die zu einem langfristigen Blutdruckabfall führt. Die Daten unterstützen die Anwendung von PB1046 bei Patienten mit essentieller Hypertonie.

For more information about this study or our company, please visit us at www.phasebio.com or contact lynne.georgopoulos@phasebio.com.

PhaseBio Pharmaceuticals Inc.

1046 Place, Malvern, PA 19355
Phone: 610-376-0000
Fax: 610-376-0001

This poster is 48" wide by 36" high. It's available as a digital copy. You can read it online or download it in PDF format.